An interesting discovery, but so are many other Swedish biopharma/biotech firms.
You can put money into these like a lottery ticket and maybe one eventually succeeds, while the rest engage in endless dilution of their share capital and wash away investors’ money. The discussion surrounding the company feels familiar—highly skeptical comments on one side, and on the other, those who are firm believers in the promises and promising trial results.
Instead of or in addition to the Swedish scene, it’s worth taking a look at US counterparts; I’ve found (there too) through filtering at least as promising rockets on their launchpads.